Funding
← Back to your selection

NAVER D2SF

Activity from announced rounds

Activity in this selectionAsia

NAVER D2SF is NAVER’s startup investment organization, identified through official materials for ImpriMed and NdotLight.

Recorded funding activity

ImpriMed combines live-cell drug testing with clinical data. NdotLight generates simulation-ready 3D data, while F4GE structures factory information for industrial buyers. The organization retains its identity separately from NAVER Ventures and the parent.

Sources
Rounds participated in
6
Confirmed lead rounds
0
5 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$20.6M
2 disclosed · full round size, not this investor’s share

By stage

Undisclosed3
Pre-seed1
Seed1
Series B1

By primary sector

Healthtech2
Robotics2
Defense tech1
Ecommerce1

By country

South Korea6

Rounds

6 in this selection
ImpriMed

A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.

$10MSeries A2 bridge
Participant
F4GE

Standardizes Korean factory data to connect manufacturers with global defense and industrial buyers

Role not disclosed
NdotLight

Generates simulation-ready 3D data for physical AI training

₩15BSeries B
Role not disclosed
SAZO

Cross-border shopping infrastructure connecting commerce platforms with payments, logistics and customs processes.

UndisclosedStrategic
Role not disclosed
Nuvilab

Develops AI-powered nutrition analytics solution for healthcare

UndisclosedUndisclosed
Role not disclosed